PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease

Article Respiratory System

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert et al.

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Respiratory System

Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study

Timothy J. W. Dawes et al.

Summary: This study investigated the potential benefit of phosphodiesterase 5 inhibitors (PDE5i) in improving survival for patients with interstitial lung disease-associated pulmonary hypertension (ILD-PH). The results showed that patients treated with PDE5i had longer survival compared to untreated patients, with a particularly significant difference when right ventricular function was normal at presentation. These findings suggest that PDE5i treatment in ILD-PH should be further studied through a prospective randomized trial.

RESPIROLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Tyler Pitre et al.

Summary: The study suggests that sildenafil may reduce mortality in patients with idiopathic pulmonary fibrosis, but its effects on lung function, acute exacerbations, and adverse reactions are uncertain.

PULMONARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Review Respiratory System

Recent advances in the management of pulmonary hypertension with interstitial lung disease

Aaron B. Waxman et al.

Summary: Pulmonary hypertension complicates interstitial lung disease and is associated with poor prognosis. Diagnosis of PH-ILD can be challenging but can be accurately determined through appropriate tests and equipment. Research on treatment options, particularly drugs for pulmonary arterial hypertension, has shown promising results.

EUROPEAN RESPIRATORY REVIEW (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)

Marc Humbert et al.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Critical Care Medicine

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

Juergen Behr et al.

Summary: The study aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo in patients with advanced IPF at risk of pulmonary hypertension. The results showed that sildenafil did not provide a treatment benefit compared to placebo up to 52 weeks, with no new safety signals identified. Further research is needed to determine if specific subgroups of IPF patients might benefit from sildenafil.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Aaron Waxman et al.

Summary: In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil significantly improved exercise capacity and clinical outcomes compared to placebo in a 16-week trial. Adverse events such as cough, headache, dyspnea, dizziness, nausea, fatigue, and diarrhea were commonly reported.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine